AU7979094A - Methods and compositions for microencapsulation of adjuvants - Google Patents

Methods and compositions for microencapsulation of adjuvants

Info

Publication number
AU7979094A
AU7979094A AU79790/94A AU7979094A AU7979094A AU 7979094 A AU7979094 A AU 7979094A AU 79790/94 A AU79790/94 A AU 79790/94A AU 7979094 A AU7979094 A AU 7979094A AU 7979094 A AU7979094 A AU 7979094A
Authority
AU
Australia
Prior art keywords
adjuvants
compositions
methods
microencapsulation
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU79790/94A
Other languages
English (en)
Inventor
Jeffrey L Cleland
Amy Lim
Michael Frank Powell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU7979094A publication Critical patent/AU7979094A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU79790/94A 1993-10-22 1994-10-13 Methods and compositions for microencapsulation of adjuvants Abandoned AU7979094A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14134193A 1993-10-22 1993-10-22
US141341 1993-10-22
US14333293A 1993-10-25 1993-10-25
US143332 1993-10-25
PCT/US1994/011674 WO1995011008A2 (fr) 1993-10-22 1994-10-13 Procedes et compositions de microencapsulation d'adjuvants

Publications (1)

Publication Number Publication Date
AU7979094A true AU7979094A (en) 1995-05-08

Family

ID=26839008

Family Applications (1)

Application Number Title Priority Date Filing Date
AU79790/94A Abandoned AU7979094A (en) 1993-10-22 1994-10-13 Methods and compositions for microencapsulation of adjuvants

Country Status (9)

Country Link
EP (1) EP0724431B1 (fr)
JP (1) JPH09504523A (fr)
AT (1) ATE223702T1 (fr)
AU (1) AU7979094A (fr)
CA (1) CA2172507C (fr)
DE (1) DE69431358T2 (fr)
DK (1) DK0724431T3 (fr)
ES (1) ES2182850T3 (fr)
WO (1) WO1995011008A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69426292T2 (de) * 1993-02-23 2001-05-17 Genentech, Inc. Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
DE69415684T2 (de) * 1993-10-22 1999-06-10 Genentech Inc., San Francisco, Calif. Verfahren zur herstellung von mikrospharen mit einer wirbelschichtstufe
CA2474701C (fr) * 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation de microparticules biodegradables contenant un agent biologiquement actif
GB9709900D0 (en) * 1997-05-15 1997-07-09 Microbiological Res Authority Microencapsulated DNA for vaccination and gene therapy
WO1997026869A1 (fr) * 1996-01-24 1997-07-31 United States Government Represented By The Secretary Of The Army Nouvelles microspheres de poly-(lactide/glucolide) a liberation prolongee 'sans eclatement'
WO1998034594A1 (fr) * 1997-02-06 1998-08-13 Merck & Co., Inc. Conservateurs sans thimerosal pour vaccins
EP1579851A3 (fr) * 1997-08-29 2009-09-02 Corixa Corporation Agents bioactifs encapsulés à libération rapide servant à initier ou à potentialiser une réponse immunitaire, et procédés d'utilisation de ceux-ci
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
JP4601823B2 (ja) 1998-09-01 2010-12-22 メリオン リサーチ スリー リミテッド 経口ワクチン組成物
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US7132108B1 (en) * 2000-02-08 2006-11-07 Agency For Science, Technology And Research Biodegradable and biocompatible polymeric microspheres encapsulating Salmonella enteritidis bacteria
ES2160089B1 (es) * 2000-03-15 2002-05-16 Inst Cientifico Tecnol Navarra Procedimiento y aparato para la produccion de microparticulas para la liberacion controlada de farmacos hidrosolubles y vectores virales. aplicacion a la adiministracion de adn plasmidico y de adenovirus recombinantes defectivos.
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
DE60238471D1 (de) * 2001-03-09 2011-01-13 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (fr) 2004-12-15 2006-06-22 Neuralab Limited Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2164467T3 (pl) * 2007-06-06 2017-07-31 Debiopharm Research & Manufacturing Sa Kompozycja farmaceutyczna o powolnym uwalnianiu wytworzona z mikrocząstek
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP3067048B1 (fr) * 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions d'induction des réponses immunitaires
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2308478A1 (fr) * 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Système de libération prolongée d'agents bloquants des canaux calciques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion

Also Published As

Publication number Publication date
CA2172507C (fr) 2008-12-02
JPH09504523A (ja) 1997-05-06
WO1995011008A3 (fr) 1996-09-19
WO1995011008A2 (fr) 1995-04-27
ATE223702T1 (de) 2002-09-15
DE69431358T2 (de) 2003-06-05
EP0724431A1 (fr) 1996-08-07
DK0724431T3 (da) 2003-01-06
CA2172507A1 (fr) 1995-04-27
ES2182850T3 (es) 2003-03-16
EP0724431B1 (fr) 2002-09-11
DE69431358D1 (de) 2002-10-17

Similar Documents

Publication Publication Date Title
AU7979094A (en) Methods and compositions for microencapsulation of adjuvants
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
PT758248E (pt) Formulacoes para o factor ix
ES2092306T3 (es) Adyuvante para vacunas.
AU1750097A (en) Highly concentrated, lyophilized, and liquid factor ix formulations
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
CA2176713A1 (fr) Derives amphiphiles d'imidazolinium
ITMI920678A1 (it) Dispositivo di ancoraggio, per esempio per componenti di mobili e simili
MY116128A (en) Vaccine composition
NZ295238A (en) Immunogenic compositions characterised by the carrier being a hydrophobic solvent in the absence of a hydrophilic phase
AU8684991A (en) Novel muramyldipeptide derivatives and influenza vaccine comprising the derivatives
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
AU7008494A (en) Methods and compositions for (salmonella)-based vaccines
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
EP0717618A4 (fr) Formulation stabilisee pour comprimes
AU1248792A (en) Influenza virus vaccine composition having a synergistic effect and containing influenza virus core as an additive
ES1023866Y (es) Dispositivo para tensar el cutis facial.
AU6709500A (en) Trehalose producing cells as vaccines
AU6400194A (en) Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
WO2000071573A3 (fr) Peptides immunogenes et utilisation associee
IT8820862V0 (it) Microirrigatore di colture di tipo dinamico.
ITRM920074A0 (it) Procedimento per la preparazione di vaccini, e vaccini cosi' ottenibili.